Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 521

1.

Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis.

Gupta R, Jamal F, Yang D, Chendri C, Aldoss I, Malki MA, Mei M, Salhotra A, Dobrin S, Tran M, Venkataraman K, Palmer J, Stein AS, Sandhu K, Khaled S, Aribi A, Marcucci G, Forman SJ, Snyder D, Nakamura R, Ali H, Pullarkat V.

Bone Marrow Transplant. 2019 Nov 6. doi: 10.1038/s41409-019-0741-8. [Epub ahead of print]

PMID:
31695170
2.

Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Gökbuget N, Kantarjian HM, Brüggemann M, Stein AS, Bargou RC, Dombret H, Fielding AK, Heffner L, Rigal-Huguet F, Litzow M, O'Brien S, Zugmaier G, Gao S, Nagorsen D, Forman SJ, Topp MS.

Blood Adv. 2019 Oct 22;3(20):3033-3037. doi: 10.1182/bloodadvances.2019000457.

3.

Massively-Parallelized, Deterministic Mechanoporation for Intracellular Delivery.

Dixit HG, Starr R, Dundon ML, Pairs PI, Yang X, Zhang Y, Nampe D, Ballas CB, Tsutsui H, Forman SJ, Brown CE, Rao MP.

Nano Lett. 2019 Oct 28. doi: 10.1021/acs.nanolett.9b03175. [Epub ahead of print]

PMID:
31647675
4.

Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.

Nakamura R, Gendzekhadze K, Palmer J, Tsai NC, Mokhtari S, Forman SJ, Zaia JA, Senitzer D, Marcucci G, Stein A.

Leuk Res. 2019 Sep 28;87:106230. doi: 10.1016/j.leukres.2019.106230. [Epub ahead of print]

PMID:
31644966
5.

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.

Siddiqi T, Frankel P, Beumer JH, Kiesel BF, Christner S, Ruel C, Song JY, Chen R, Kelly KR, Ailawadhi S, Kaesberg P, Popplewell L, Puverel S, Piekarz R, Forman SJ, Newman EM.

Leuk Lymphoma. 2019 Oct 16:1-9. doi: 10.1080/10428194.2019.1672052. [Epub ahead of print]

PMID:
31617432
6.

Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation.

Mascarenhas K, Teh JB, Peng K, Kim H, Sy A, Forman SJ, Wong FL, Nakamura R, Dadwal SS, Armenian SH.

Bone Marrow Transplant. 2019 Oct 15. doi: 10.1038/s41409-019-0717-8. [Epub ahead of print] No abstract available.

PMID:
31616064
7.

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen CW, Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, Kwak LW.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw9414. doi: 10.1126/scitranslmed.aaw9414.

PMID:
31554741
8.

Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation.

Malki MMA, Gendzekhadze K, Stiller T, Mokhtari S, Karanes C, Parker P, Snyder D, Forman SJ, Nakamura R, Nademanee A.

Bone Marrow Transplant. 2019 Sep 24. doi: 10.1038/s41409-019-0694-y. [Epub ahead of print]

PMID:
31551519
9.

Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.

Salhotra A, Hui S, Yang D, Mokhtari S, Mei M, Al Malki MM, Aldoss I, Ali H, Sandhu KS, Aribi A, Khaled S, Dandapani S, Peng K, Teh JB, Murata-Collins J, Budde E, Dadwal S, Pullarkat V, Snyder D, Spielberger R, Wong J, Armenian S, Marcucci G, Forman SJ, Nakamura R, Stein A.

Biol Blood Marrow Transplant. 2019 Sep 16. pii: S1083-8791(19)30628-7. doi: 10.1016/j.bbmt.2019.09.017. [Epub ahead of print]

PMID:
31536825
10.

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L.

Cell Stem Cell. 2019 Oct 3;25(4):542-557.e9. doi: 10.1016/j.stem.2019.08.004. Epub 2019 Sep 5.

PMID:
31495780
11.

Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation.

Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S.

Cancer. 2019 Aug 30. doi: 10.1002/cncr.32488. [Epub ahead of print]

PMID:
31469420
12.

Long-term outcome of allogeneic hematopoietic stem cell transplantation from unrelated donor using tacrolimus/sirolimus-based GVHD prophylaxis: impact of HLA mismatch.

Al Malki MM, Gendzekhadze K, Yang D, Mokhtari S, Parker P, Karanes C, Palmer J, Snyder D, Forman SJ, Nademanee A, Nakamura R.

Transplantation. 2019 Aug 19. doi: 10.1097/TP.0000000000002932. [Epub ahead of print]

PMID:
31449184
13.

Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation.

Slavin TP, Teh JB, Weitzel JN, Peng K, Wong FL, Qin H, Wang J, Wu X, Mei M, Pillai R, Wang Y, Tsang KK, Pozhitkov A, Krishnan A, Forman SJ, Armenian SH.

Biol Blood Marrow Transplant. 2019 Aug 22. pii: S1083-8791(19)30527-0. doi: 10.1016/j.bbmt.2019.08.013. [Epub ahead of print]

14.

Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.

Aldoss I, Zhang J, Pillai R, Shouse G, Sanchez JF, Mei M, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Br J Haematol. 2019 Oct;187(2):e45-e48. doi: 10.1111/bjh.16166. Epub 2019 Aug 22. No abstract available.

PMID:
31441045
15.

Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.

Jabbour EJ, Gökbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS.

Cancer. 2019 Dec 1;125(23):4181-4192. doi: 10.1002/cncr.32335. Epub 2019 Aug 21.

PMID:
31433496
16.

Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.

Wu J, Chen Y, Hageman L, Francisco L, Ness EC, Parman M, Kung M, Watson JA, Weisdorf DJ, Snyder DS, McGlave PB, Forman SJ, Arora M, Armenian SH, Bhatia R, Bhatia S.

Cancer. 2019 Nov 15;125(22):4033-4042. doi: 10.1002/cncr.32443. Epub 2019 Aug 14.

PMID:
31412155
17.

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma.

Herrera AF, Chen L, Khajavian S, Chase M, Darrah J, Maloney D, Ho VT, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Chen YB, Armand P, Shadman M.

Biol Blood Marrow Transplant. 2019 Aug 5. pii: S1083-8791(19)30513-0. doi: 10.1016/j.bbmt.2019.07.041. [Epub ahead of print]

PMID:
31394277
18.

The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.

Otoukesh S, Salhotra A, Marcucci G, Forman SJ, Pullarkat V, Aldoss I.

Leuk Res. 2019 Sep;84:106196. doi: 10.1016/j.leukres.2019.106196. Epub 2019 Jul 30. No abstract available.

PMID:
31377457
19.

Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.

Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2160-2166. doi: 10.1016/j.bbmt.2019.06.033. Epub 2019 Jul 4.

PMID:
31279752
20.

Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study.

Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Battles K, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2261-2266. doi: 10.1016/j.bbmt.2019.06.032. Epub 2019 Jul 3.

PMID:
31278995
21.

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Aldoss I, Yang D, Pillai R, Sanchez JF, Mei M, Aribi A, Ali H, Sandhu K, Al Malki MM, Salhotra A, Khaled S, Sun W, O'Donnell M, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Am J Hematol. 2019 Oct;94(10):E253-E255. doi: 10.1002/ajh.25567. Epub 2019 Jul 10. No abstract available.

PMID:
31259427
22.

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

Salhotra A, Afkhami M, Yang D, Mokhtari S, Telatar M, Gu D, Pillai RK, Weisenburger DD, Murata-Collins J, Weigel D, Aoun P, Aldoss I, Al Malki MM, Khaled S, Mei M, Ali H, Aribi A, Budde E, Sandhu K, O'Donnell M, Snyder D, Pullarkat V, Forman SJ, Marcucci G, Nakamura R, Stein A.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e400-e405. doi: 10.1016/j.clml.2019.04.007. Epub 2019 Apr 26.

PMID:
31155409
23.

CD123 CAR T cells for the treatment of myelodysplastic syndrome.

Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E.

Exp Hematol. 2019 Jun;74:52-63.e3. doi: 10.1016/j.exphem.2019.05.002. Epub 2019 May 25.

24.

Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia.

Aldoss I, Nakamura R, Yang D, Salhotra A, Stein AS, Pullarkat V, Forman SJ, Marcucci G.

Bone Marrow Transplant. 2019 May 14. doi: 10.1038/s41409-019-0553-x. [Epub ahead of print] No abstract available.

PMID:
31089274
25.

Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation.

Armenian SH, Xiao M, Berano Teh J, Lee B, Chang HA, Mascarenhas K, Lee S, Iukuridze A, Xie JJ, Scott JM, Jones LW, Lennie Wong F, Forman SJ, Nakamura R.

J Natl Cancer Inst. 2019 Feb 14. pii: djy231. doi: 10.1093/jnci/djy231. [Epub ahead of print]

PMID:
30951603
26.

IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.

Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, Aguilar B, Qi Y, Ann DK, Starr R, Urak R, Wang X, Forman SJ, Brown CE.

Cancer Immunol Res. 2019 May;7(5):759-772. doi: 10.1158/2326-6066.CIR-18-0466. Epub 2019 Mar 19.

PMID:
30890531
27.

Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study.

Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S.

Br J Haematol. 2019 Jul;186(2):367-370. doi: 10.1111/bjh.15866. Epub 2019 Mar 18. No abstract available.

PMID:
30883690
28.

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function.

Wang D, Starr R, Alizadeh D, Yang X, Forman SJ, Brown CE.

J Vis Exp. 2019 Feb 27;(144). doi: 10.3791/59275.

29.

Acute Lymphoblastic Leukemia in the Older Adult.

Aldoss I, Forman SJ, Pullarkat V.

J Oncol Pract. 2019 Feb;15(2):67-75. doi: 10.1200/JOP.18.00271.

PMID:
30763199
30.

Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.

Mei M, Gupta R, O'Donnell M, Al Malki MM, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, Khaled S.

Biol Blood Marrow Transplant. 2019 May;25(5):e183-e185. doi: 10.1016/j.bbmt.2019.01.025. Epub 2019 Jan 29.

PMID:
30708188
31.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.

Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ.

Leuk Lymphoma. 2019 Aug;60(8):1934-1941. doi: 10.1080/10428194.2018.1563691. Epub 2019 Jan 10.

PMID:
30628511
32.

The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.

Nguyen LXT, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, Zhang B, Nguyen DQ, Aldoss I, Ghoda L, Budde E, Pichiorri F, Rosen S, Forman SJ, Marcucci G, Pullarkat V.

J Cell Physiol. 2019 Aug;234(8):14040-14049. doi: 10.1002/jcp.28091. Epub 2019 Jan 8.

PMID:
30623427
33.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, Afkhami M, Al Malki MM, Cao T, Mei M, O'Donnell M, Salhotra A, Pullarkat V, Yang L, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pillai R, Snyder D.

Blood Adv. 2019 Jan 8;3(1):83-95. doi: 10.1182/bloodadvances.2018026658.

34.

Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.

Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ.

Front Immunol. 2018 Nov 19;9:2268. doi: 10.3389/fimmu.2018.02268. eCollection 2018.

35.

Adults with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission.

Aldoss I, Kamal MO, Forman SJ, Pullarkat V.

Biol Blood Marrow Transplant. 2019 Feb;25(2):e41-e45. doi: 10.1016/j.bbmt.2018.09.041. Epub 2018 Oct 5.

PMID:
30292743
36.

Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

Salhotra A, Mei M, Stiller T, Mokhtari S, Herrera AF, Chen R, Popplewell L, Zain J, Ali H, Sandhu K, Budde E, Nademanee A, Forman SJ, Nakamura R.

Biol Blood Marrow Transplant. 2019 Feb;25(2):287-292. doi: 10.1016/j.bbmt.2018.09.009. Epub 2018 Sep 15.

PMID:
30227232
37.

Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.

Holmqvist AS, Chen Y, Wu J, Battles K, Bhatia R, Francisco L, Hageman L, Kung M, Ness E, Parman M, Salzman D, Wadhwa A, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, Armenian SH, Arora M, Bhatia S.

JAMA Oncol. 2018 Dec 1;4(12):e182453. doi: 10.1001/jamaoncol.2018.2453. Epub 2018 Dec 13.

38.

Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.

Armenian SH, Yang D, Teh JB, Atencio LC, Gonzales A, Wong FL, Leisenring WM, Forman SJ, Nakamura R, Chow EJ.

Blood Adv. 2018 Jul 24;2(14):1756-1764. doi: 10.1182/bloodadvances.2018019117.

39.

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.

Aldoss I, Capelletti M, Park J, Pistofidis RS, Pillai R, Stiller T, Sanchez JF, Forman SJ, Ghobrial IM, Krishnan A.

Leukemia. 2019 Jan;33(1):266-270. doi: 10.1038/s41375-018-0213-y. Epub 2018 Jul 19.

PMID:
30026571
40.

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.

Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, Nademanee AP, Siddiqi T, Tsai NC, Chen L, Zuo F, Abary R, Cai JL, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LW, Holmberg LA.

J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3.

41.

Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.

Holmqvist AS, Chen Y, Wu J, Kung M, Ness E, Parman M, Francisco L, Hageman L, Battles K, Bhatia R, Salzman D, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, Armenian SH, Arora M, Bhatia S.

Leukemia. 2018 Dec;32(12):2706-2709. doi: 10.1038/s41375-018-0171-4. Epub 2018 Jun 26. No abstract available.

PMID:
29946190
42.

Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.

Aldoss I, Stiller T, Tsai NC, Song JY, Cao T, Bandara NA, Salhotra A, Khaled S, Aribi A, Al Malki MM, Mei M, Ali H, Spielberger R, O'Donnell M, Snyder D, Slavin T, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Haematologica. 2018 Oct;103(10):1662-1668. doi: 10.3324/haematol.2018.193599. Epub 2018 Jun 14.

43.

Regulation of miR-34b/c-targeted gene expression program by SUMOylation.

Li YJ, Du L, Aldana-Masangkay G, Wang X, Urak R, Forman SJ, Rosen ST, Chen Y.

Nucleic Acids Res. 2018 Aug 21;46(14):7108-7123. doi: 10.1093/nar/gky484.

44.

Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity.

Wang D, Aguilar B, Starr R, Alizadeh D, Brito A, Sarkissian A, Ostberg JR, Forman SJ, Brown CE.

JCI Insight. 2018 May 17;3(10). pii: 99048. doi: 10.1172/jci.insight.99048. eCollection 2018 May 17.

45.

Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Al Malki MM, Nathwani N, Yang D, Armenian S, Dadwal S, Salman J, Mokhtari S, Cao T, Sandhu K, Rouse M, Mei M, Ali H, Parker P, Alvarnas J, Smith E, Donnell MO, Marcucci G, Snyder D, Nademanee A, Forman SJ, Stein A, Nakamura R.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1828-1835. doi: 10.1016/j.bbmt.2018.04.029. Epub 2018 May 9.

46.

PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine.

Weist MR, Starr R, Aguilar B, Chea J, Miles JK, Poku E, Gerdts E, Yang X, Priceman SJ, Forman SJ, Colcher D, Brown CE, Shively JE.

J Nucl Med. 2018 Oct;59(10):1531-1537. doi: 10.2967/jnumed.117.206714. Epub 2018 May 4.

47.

A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes.

van Megen KM, van 't Wout ET, Forman SJ, Roep BO.

Front Immunol. 2018 Apr 6;9:690. doi: 10.3389/fimmu.2018.00690. eCollection 2018. No abstract available.

48.

Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report.

Holmqvist AS, Chen Y, Wu J, Battles K, Bhatia R, Francisco L, Hageman L, Kung M, Ness E, Parman M, Salzman D, Winther JF, Rosenthal J, Forman SJ, Weisdorf DJ, Arora M, Armenian SH, Bhatia S.

Blood. 2018 Jun 14;131(24):2720-2729. doi: 10.1182/blood-2018-02-831156. Epub 2018 Apr 16.

49.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O'Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15. No abstract available.

50.

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.

Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, Lin A, Pellicano F, Hopcroft L, Su YL, Copland M, Holyoake TL, Kuo CJ, Bhatia R, Snyder DS, Ali H, Stein AS, Brewer C, Wang H, McDonald T, Swiderski P, Troadec E, Chen CC, Dorrance A, Pullarkat V, Yuan YC, Perrotti D, Carlesso N, Forman SJ, Kortylewski M, Kuo YH, Marcucci G.

Nat Med. 2018 May;24(4):450-462. doi: 10.1038/nm.4499. Epub 2018 Mar 5.

Supplemental Content

Loading ...
Support Center